An P.

An P. currently serves as Senior Medical Director for Breast Cancer Strategy at Genentech, leading the launch execution of inavolisib for first-line HR+, HER2- metastatic breast cancer and supporting its development across multiple tumor types. Previous experience includes roles as Senior Medical Director overseeing various cancer portfolios, including anti-PDL1 Tecentriq, and as Director of Global Oncology at Merck, focusing on genitourinary cancers. An P. has a strong foundation in medical affairs and oncology, having launched key therapies such as pembrolizumab and sotorasib. Educationally, An P. is pursuing an MBA in Healthcare Management, Innovation, and Technology from The Johns Hopkins University and has completed an executive program at UCLA Anderson School of Management.